<div id="readability-page-1"><div> <div> Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information], /PRNewswire/ -- Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (&#34;Regencell&#34; or the &#34;Company&#34;) (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. </div> </div><div> <div> Faruqi &amp; Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. The truth began to emerge on October 31, 2025, when Regencell disclosed in an SEC filing that &#34;following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice ('DOJ'), indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares.&#34; Regencell said that &#34;[t] he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters&#34; and that the Company &#34;expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation&#34; and &#34;may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation.&#34;On this news, Regencell's ordinary share price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.Faruqi &amp; Faruqi, LLP also encourages anyone with information regarding Regencell's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the Regencell Bioscience class action, go to www.faruqilaw.com/RGC or call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi &amp; Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE Faruqi &amp; Faruqi, LLP<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE1Jk5ld3NJdGVtSWQ9Tlk2MDE5MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTUwODEyUFJfTkVXU19VU1BSX19fX19OWTYwMTkx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE1Jk5ld3NJdGVtSWQ9Tlk2MDE5MSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTUwODEyUFJfTkVXU19VU1BSX19fX19OWTYwMTkx"/></div> </div></div>

SBIO

ARKG

LABU

Faruqi & Faruqi, LLP is investigating potential claims against Regencell Bioscience Holdings Limited and reminds investors of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm alleges that Regencell made false statements and failed to disclose vulnerabilities, leading to significant financial risks for investors. Following a DOJ investigation announcement, Regencell's share price fell 18.56%. Investors who suffered losses are encouraged to contact the firm for legal options.

prnewswire

Regencell Bioscience

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

08:12 ETRGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026